Browsing by 저자 : 류백렬
전체 결과 52건 중 1-52 번을 표시중입니다.
- 1 Article A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies & Bhumsuk Keam ; 류백렬 ; Chia-Chi Lin ; et al 2020
- 2 Article Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients 권재우 ; 김규표 ; 김명환 ; et al 2021
- 3 Article Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study 류백렬 ; Aiwu Ruth He ; Bo Liu ; et al 2020
- 4 Article Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index < 55%: single-arm phase II study 김규표 ; 김용일 ; 류백렬 ; et al 2021
- 5 Article Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer Prognosis 김주영 ; 김지섭 ; 류백렬 ; et al 2020
- 6 Article Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy 김규표 ; 류백렬 ; 방경혜 ; et al 2021
- 7 Article Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma 강효정 ; 김강모 ; 김규표 ; et al 2021
- 8 Article Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study 김강모 ; 김좌훈 ; 류백렬 ; et al 2021
- 9 Article Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review 김규표 ; 류백렬 ; 박준오 ; et al 2021
- 10 Article Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study 김강모 ; 류백렬 ; 박숙련 ; et al 2020
- 11 Article Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response 강준호 ; 김규표 ; 김기훈 ; et al 2020
- 12 Article Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis 강명주 ; 김규표 ; 김일환 ; et al 2020
- 13 Article Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma 류백렬 ; 박숙련 ; Beatriz Lopez ; et al 2021
- 14 Article Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin 김규표 ; 류백렬 ; 박도현 ; et al 2021
- 15 Article Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin 김규표 ; 류백렬 ; 박도현 ; et al 2021
- 16 Article FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma 유창훈 ; 황인환 ; 송태준 ; et al 2020
- 17 Article Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240 류백렬 ; Abby B Siegel ; Amit S Kulkarni ; et al 2021
- 18 Article How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers 구하영 ; 김규표 ; 김선영 ; et al 2020
- 19 Article Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 김형돈 ; 류백렬 ; 방영학 ; et al 2021
- 20 Article Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma 김강모 ; 김지윤 ; 류백렬 ; et al 2021
- 21 Article Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study 강명주 ; 강병욱 ; 김경원 ; et al 2021
- 22 Article Lymphocyte to monocyte ratio?based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib 김강모 ; 류백렬 ; 이한주 ; et al 2020
- 23 Article Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison wit 류백렬 ; Andres Munoz ; Annie Hung ; et al 2020
- 24 Article Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival 권재우 ; 김규표 ; 김송철 ; et al 2021
- 25 Article Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer 강지훈 ; 김규표 ; 김송철 ; et al 2021
- 26 Article Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer 강지훈 ; 김규표 ; 김송철 ; et al 2021
- 27 Article Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis 김규표 ; 김명환 ; 김송철 ; et al 2020
- 28 Article Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO 류백렬 ; A Cervantes ; A Vogel ; et al 2020
- 29 Article Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial 류백렬 ; Chao Y. ; Chen E. ; et al 2021
- 30 Article PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer 강윤구 ; 국명철 ; 김균지 ; et al 2021
- 31 Article Prognostic Value of 18F-FDG PET in Neuroendocrine Neoplasm 김태형 ; 류백렬 ; 류진숙 ; et al 2021
- 32 Article Radiation therapy for recurrent extrahepatic bile duct cancer 고민지 ; 김규표 ; 김종훈 ; et al 2021
- 33 Article Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression 류백렬 ; Ann-Li Cheng ; Chia Jui Yen ; et al 2021
- 34 Article Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) 류백렬 ; Andres J Munoz Martin ; Charles D Lopez ; et al 2021
- 35 Article Real-world data analysis of patients with cancer of unknown primary 강소라 ; 김규표 ; 김정은 ; et al 2021
- 36 Article Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis 김강모 ; 류백렬 ; 박능화 ; et al 2020
- 37 Article Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer 이우형 ; 박예종 ; 권재우 ; et al 2020
- 38 Article Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study 강명주 ; 강버들 ; 강정헌 ; et al 2020
- 39 Article Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events 강명주 ; 김일환 ; 류백렬 ; et al 2020
- 40 Article Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 김형돈 ; 류백렬 ; 방영학 ; et al 2021
- 41 Article Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma 김강모 ; 류백렬 ; 박숙련 ; et al 2020
- 42 Article Rivaroxaban Versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer 김규표 ; 김좌훈 ; 류백렬 ; et al 2020
- 43 Article Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 김형돈 ; 류백렬 ; 방영학 ; et al 2021
- 44 Article Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial 류백렬 ; Ann-Lii Cheng ; Anthony B El-Khoueiry ; et al 2020
- 45 Article Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 김형돈 ; 류백렬 ; 박숙련 ; et al 2021
- 46 Article Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3(-) CD4(+) T Cells in Biliary Tract Cancer 김규표 ; 김기훈 ; 김단비 ; et al 2021
- 47 Article Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3(-) CD4(+) T Cells in Biliary Tract Cancer 김규표 ; 김기훈 ; 김단비 ; et al 2021
- 48 Article Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion 김승태 ; 류백렬 ; 배우균 ; et al 2021
- 49 Article Tumour-to-liver ratio determined by [Ga-68]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours 강준호 ; 김용일 ; 류백렬 ; et al 2020
- 50 Article Value of 18F-FDG PET in Neuroendocrine Neoplasm: A Systematic Review and Meta-analysis 김태형 ; 류백렬 ; 류진숙 ; et al 2021
-
51
Dissertation
담도암 환자로부터 암세포주와 이종이식의 수립
강지훈
2020
-
52
Dissertation
이리노테칸 항암 요법 시행 후 진행한 전이성 췌장암 환자에서 리포좀 이리노테칸 및 플루오로우라실/류코보린 병합 요법에 대한 연구
방경혜
2020
1